Can a smart drug deliver a direct hit to Hard-to-Treat tumors?
NCT ID NCT07744763
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing an experimental drug called SYS6041 in people with advanced solid tumors. SYS6041 is designed to seek out and attach to a protein called FRα that is found on some cancer cells, delivering a potent anti-cancer agent directly to the tumor. The study aims to find the safest dose and see whether the drug can shrink tumors. It is open to adults with advanced solid tumors who have at least one measurable lesion and are willing to provide a tumor sample for testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYS6041, an antibody-drug conjugate that targets a protein called FRα found on some tumor cells, delivering a chemotherapy-like drug directly to the cancer.
- What this could lead to
- If successful, this could lead to a new targeted treatment option for people with advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is an early-stage trial, so the drug may not be safe or effective in humans. Potential risks include side effects from the chemotherapy component and the possibility that the tumor does not respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiaohua
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.